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Abstract
Background: Methylation profiling of tumor suppressor gene (TSGs) promoters is quickly becoming a powerful diagnostic
tool for the early detection, prognosis, and even prediction of clinical response to treatment. Few studies address this in
salivary gland tumors (SGTs); hence the promoter methylation profile of various TSGs was quantitatively assessed in primary
SGT tissue to determine if tumor-specific alterations could be detected.
Methodology: DNA isolated from 78 tumor and 17 normal parotid gland specimens was assayed for promoter methylation
status of 19 TSGs by fluorescence-based, quantitative methylation-specific PCR (qMSP). The data were utilized in a binary
fashion as well as quantitatively (using a methylation quotient) allowing for better profiling and interpretation of results.
Principal Findings: The average number of methylation events across the studied genes was highest in salivary duct
carcinoma (SDC), with a methylation value of 9.6, compared to the normal 4.5 (p,0.0003). There was a variable frequency and
individual methylation quotient detected, depending on the TSG and the tumor type. When comparing normal, benign, and
malignant SGTs, there was a statistically significant trend for increasing methylation in APC, Mint 1, PGP9.5, RAR-b, and Timp3.
Conclusions/Significance: Screening promoter methylation profiles in SGTs showed considerable heterogeneity. The
methylation status of certain markers was surprisingly high in even normal salivary tissue, confirming the need for such
controls. Several TSGs were found to be associated with malignant SGTs, especially SDC. Further study is needed to evaluate
the potential use of these associations in the detection, prognosis, and therapeutic outcome of these rare tumors.
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Introduction
Salivary gland tumors (SGTs) represent a diverse group of tumor
types with a wide range of biological behaviors and histopathologic
characteristics, which complicates their diagnosis and management
[1,2]. Approximately 40% of these tumors are malignant, and SGTs
comprise about 5% of all head and neck malignancies, which equals
only 0.3% of all malignant neoplasms [2,3,4].
The variable nature of SGTs creates difficulty in determining
prognosis. Outcomes for patients with SGTs depend on the site of
tumor, histology, extent of disease, completeness of surgery, and/
or adjuvant radiation therapy, though there are many exceptions
[5]. The classic example is adenoid cystic carcinoma where,
despite thorough resection, up to 60% of patients experience
locoregional or distant metastases. The median survival in the
presence of distant metastases is around three years, though
surprisingly, up to 10% of these patients may survive 10 years or
longer with their metstases [6]. Thus, the behavior of this
malignancy is quite variable and leads to much uncertainty for
the patients afflicted with this disease. Even the most common
‘benign’ salivary tumor, pleomorphic adenoma, has a propensity
for malignant transformation and possible recurrence.
The pathogenesis of human cancer is a heterogeneous process
involving several pathways, and it has been proposed that the
genotype may affect the clinical behavior and prognosis of the
tumor [7,8]. Recent studies have shown that development and
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of alterations in tumor suppressor genes (TSGs) and proto-
oncogenes, and this appears to be true for some SGTs [9,10,11].
It is well documented that epigenetic alterations, such as DNA
methylation and histone acetylation are important factors in
human carcinogenesis. Methylation of cytosines in cytosine-
guanine (CpG) islands contained within gene promoters can lead
to transcriptional inactivation by blocking the RNA polymerase
complex from binding to the promoter region. Inactivation of
TSGs by hypermethylation of these CpG islands is a common
feature of human carcinogenesis across many tumor types as it is
associated with a partial or complete transcriptional block [12].
Methylation profiling of TSGs is quickly becoming a powerful
diagnostic tool for the early detection, prognosis, and even
prediction of clinical response to treatment of various cancers [13].
The etiology of most SGTs has not been determined, and little
is known about the epigenetic alterations occurring within this
class of neoplasms. Previous studies looking at the clinical
significance of TSG promoter hypermethylation in SGTs used
non-quantitative MSP and focused on a limited number of genes.
There is only one other quantitative study done by Lee et al. that
looked at promoter hypermethylation in salivary gland carcinomas
using pyrosequencing, but surveyed the methylation status of only
3 genes [14]. In addition, the results from these studies have not
been reproduced in a second independent study [15,16,17,18].
Thus, there is a real need for more clarity regarding the
association of TSG hypermethylation and SGTs, as this could
lead to functional studies that could further elucidate the biology of
this group of neoplasms [7]. An improved understanding of the
molecular alterations associated with salivary gland tumors has the
potential to improve the diagnosis, management, and outcomes
seen in this patient population.
In this study we used quantitative MSP to determine the
methylation frequencies and quantitative methylation values of
nineteen known tumor suppressor genes in 78 SGT patients and
17 normal parotid tissue samples. Quantitative MSP has been
successfully used in other tumor models and has the benefit of
providing accurate and precise data regarding the level of
methylation in the various tumors. Six of the genes we evaluated,
including cyclin-dependent kinase inhibitor 2A (p16), stratifin 14-3-3s,
RAS-associated domain family protein 1A (RASSF1A), retinoic acid receptor
b (RAR-b), death-associated protein kinase (DAPK), and O
6-methylgua-
nine-DNA-methyltransferase (MGMT), were previously shown to be
aberrantly methylated in salivary gland cancer [5,7,8,11,18,19,20].
The remaining thirteen genes we studied have been implicated in
other cancer types; these genes include absent in melanoma-1 (AIM1),
adenomatous polyposis coli (APC), b-catenin, deleted in colorectal carcinoma
(DCC), fragile histidine triad (FHIT), glutathione S-transferase P1
(GSTP1), hypermethylated in cancer-1 (HIC1), methylated in tumor-1
(Mint1), mismatch repair protein (MLH1), protein gene product 9.5
(PGP9.5), thrombospondin-1 (THBS1), tissue inhibitor of metalloproteinase-
3 (TIMP3), and target of methylation induced silencing-1 (TMS1)
[21,22,23,24]. The aim of this study was to compare the promoter
methylation profiles of benign SGTs (PA), and malignant SGTs
(MEC, ACC, and SDC) along with normal parotid gland tissue in
order to better understand the role of epigenetic silencing in
salivary gland tumorigenesis.
Materials and Methods
Tissue samples
Tumor samples from 17 normal salivary gland specimens, and
78 paraffin embedded tumor specimens were obtained from
patients surgically treated at the Department of Otolaryngology-
Head and Neck Surgery (Johns Hopkins Medical Institution,
Baltimore, MD, USA) using appropriate written informed consent
obtained after approval by the Johns Hopkins Institutional Review
Board. There were a total of 26 benign tumor samples and 52
malignant tumor samples. All 26 benign samples were pleomor-
phic adenomas (PA). The malignant samples included 17 adenoid
cystic carcinomas (ACC), 18 salivary ductal carcinomas (SDC),
and 17 mucoepidermoid carcinomas (MEC).
DNA extraction
Paraffin embedded tissues sections were made and microdissected
to ensure tumor purity. After de-paraffinization by xylene treatment,
total genomic DNA was extracted by digestion with 50 mg/ml
proteinase K (Boehringer, Mannheim, Germany) in the presence of
1% SDS at 48uC overnight, followed by phenol/chloroform
extraction and ethanol precipitation. Genomic DNA was eluted in
low-salt Tris-EDTA (LoTE) buffer and stored at 220uC.
Bisulfite Treatment
DNA from primary tumors and normal controls were subjected
to bisulfite treatment, which modifies CpG islands including those
of TSG promoters, using the Epitect Bisulfite Kit from Qiagen
(Valencia, California). The bisulfite-modified genomic DNA was
resuspended in 120–150 uL of H2O and stored at 280uC.
Quantitative Methylation-specific PCR (qMSP)
The bisulfite-modified DNA was used as a template for
fluorescence-based real-time polymerase chain reaction (PCR),
as previously described [25]. In brief, we evaluated the promoter
methylation profiles of TSGs by fluorescence-based quantitative
methylation-specific PCR (qMSP). Methylation specific primers
and probes were designed to specifically amplify the bisulfite-
modified promoters of the gene of interest (Table 1).
Fluorogenic PCRs were carried out in a reaction volume of 20 mL
consisting of 600 nM of each primer; 200mMo fp r o b e ;0 . 7 5Uo f
platinum Taq polymerase (Invitrogen, Carlsbad, CA); 200 mMo f
each dATP, dCTP, dGTP, and dTTP; 200nM of ROX dye for
reference (Invitrogen, Carlsbad, CA); 16.6 mmol/L of ammonium
sulfate; 67 mmol/L of Trizma (Sigma, St Louis, MO); 6.7 mmol/L
of magnesium chloride; 10 mmol/L of mercaptoethanol; and 0.1%
dimethylsulfoxide. Three microliters of treated DNA solution were
used in each real-time MSP reaction. Amplifications were carried out
in 384-well plates in a 7900 Sequence Detector System (Perkin-Elmer
Applied Biosystems, Norwalk, CT). Thermal cycling was initiated
with a first denaturation step at 95uCf o r2m i n u t e s ,f o l l o w e db y4 5
cycles of 95uC for 15 seconds and 60uC for 1 minute. Leukocytes
from a healthy individual were methylated in vitro with excess SssI
methyltransferase (New England Biolabs Inc, Beverly, MA) to
generate completely methylated DNA, and serial dilutions of this
DNA were used for constructing the calibration curves on each
plate. Each reaction was performed in triplicate to ensure consistent
results.
The TSG promoter methylation level in each sample was
calculated and normalized with respect to an internal reference
gene, b-actin. This measure, which we will further refer to as
methylation quotient (MQ), represents the relative level of
methylation in a particular sample [(gene of interest/reference
gene) 61000] and was used for direct comparison of samples.
In order for a tumor sample to be considered methylated at a
specific TSG, it had to meet two specific criteria. Amplification
must have been present in at least 2 of the 3 reaction wells in the
triplicate run, and the mean methylation quotient must have fallen
within the range of the serial standard curve dilutions. The lack of
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of a distilled water negative control for each qMSP run.
Statistical Analysis
The primary objective in this study was to describe the
methylation patterns of 19 tumor suppressor genes in normal
tissue and four salivary gland tumor types: ACC, SDC, MEC and
PA. To compare overall methylation levels by tumor type, the
number of methylated genes for each patient was calculated as the
sum of genes with any degree of methylation and the average value
for normal samples was compared to the average for each tumor
type using an analysis of variance.
Continuous distributions of qMSP ratios are usually skewed,
often with a clump of zeros in the lower tail of the distribution.
To determine if increasing methylation of any of the selected
genes was seen across three categories of samples: normal, benign
and malignant, two types of analyses were considered. To
evaluate presence or absence of methylation for each gene, an
exact version of the Cochran-Armitage trend test [26] was used to
determine if the probability of methylation increased across the
three categories. To evaluate the continuous methylation
distributions of each gene across normal, benign and malignant
categories, the non-parametric Cuzick test [27] for trend was
used. All statistical computations were performed using the SAS
system [28], StatXact [29] or R [30]. All p values reported are
two sided.
Results
Clinical and Pathological Data
A total of 19 gene promoter regions were analyzed for
methylation of CpG islands in 78 patients with salivary gland
tumors and 17 normal salivary gland samples. The clinical and
pathological characteristics of these patients, including age and
smoking status, are depicted in Table 2. Of the 78 patients with
salivary gland tumors, 35 were male and 43 were female and ages
ranged from 12 to 85 years at the time of diagnosis. Of the 17
patients with ACC, 2 (11.8%) eventually developed local
recurrence and 10 (58.8%) developed distant metastases. Of the
17 patients with MEC, 1 (5.9%) developed local recurrence and
another 2 (11.8%) distant metastasis. As expected, none of the 26
patients with PA developed distant metastases, but 1 (3.8%)
developed local recurrence. Of the 18 patients with SDC, 8
(44.4%) developed local recurrence and the same number
developed distant metastases. The mean follow-up time for
patients with malignancy (ACC, MEC, or SDC) was 3.2 years
(range 0.01–18 years).
Quantitative Methylation-Specific PCR in Salivary Gland
Tissues
The average number of methylated genes per tissue type is
shown in Table 3. As demonstrated, the number of methylated
TSGs were significantly higher in SDC compared to normal
salivary tissue (p,0.0003), but there was no apparent difference
between normal and PA, MEC, or ACC.
The individual methylation frequency (percentage of all samples
showing some degree of methylation) and mean methylation
quotient (MQ as defined previously) values for the 19 TSG loci are
listed in Table 4. At least one TSG locus was methylated in 77/78
tumor samples (98.7%), and a total of 73/78 tumor samples
(93.6%) showed methylation at 3 or more of the loci. The
methylation frequencies varied from 0 to over 100% for different
TSGs in all four tumor types, and interestingly, this was also true
of the normal salivary tissue.
Table 1. Primer and probe sequences for candidate tumor suppressor genes.
Gene Forward primer sequence (59-39) Reverse primer sequence (59-39) Probe sequence (59Fam-39Tamra)
Aim1 CGC GGG TAT TGG ATG TTA GT CCG ACC CAC CTA TAC GAA AA GGG AGC GTT GCG GAT TAT TCG TAG
APC GAA CCA AAA CGC TCC CCA T TTA TAT GTC GGT TAC GTG CGT TTA TAT CCC GTC GAA AAC CCG CCG ATT A
b-catenin GGA AAG GCG CGT CGA GT TCC CCT ATC CCA AAC CCG CGC GCG TTT CCC GAA CCG
DAP-K GGA TAG TCG GAT CGA GTT AAC GTC CCC TCC CAA ACG CCG A TTC GGT AAT TCG TAG CGG TAG GGT TTG G
DCC TTG TTC GCG ATT TTT GGT TTC ACC GAT TAC TTA AAA ATA CGC G GCG CTA AAC AAA AAA ACT CCG AAA A
FHIT GGG CGC GGG TTT GGG TTT TTA C GAA ACA AAA ACC CAC CGC CCC G AAC GAC GCC GAC CCC ACT AAA CTC C
GSTP1 AGT TGC GCG GCG ATT TC GCC CCA ATA CTA AAT CAC GAC G CGG TCG ACG TTC GGG GTG TAG CG
HIC1 GTT AGG CGG TTA GGG CGT C CCG AAC GCC TCC ATC GTA T CAA CAT CGT CTA CCC AAC ACA CTC TCC TAC G
MGMT CGA ATA TAC TAA AAC AAC CCG CG GTA TTT TTT CGG GAG CGA GGC AAT CCT CGC GAT ACG CAC CGT TTA CG
Mint1 ATT TTC GAA GCG TTT GTT TGG C ACA AAA AAC CTC AAC CCC GC GCG AAA CTC CCC TAC TCT CCA AC
MLH1 CGT TAT ATA TCG TTC GTA GTA TTC GTG TTT CTA TCG CCG CCT CAT CGT CGC GAC GTC AAA CGC CAC TAC G
p16 TTA TTA GAG GGT GGG GCG GAT CGC GAC CCC GAA CCG CGA CCG TAA AGT AGT ATG GAG TCG GCG GCG GG
PGP 9.5 CGG CGA GTG AGA TTG TAA GGT T GAA CGA TCG CGA CCA AAT AAA TAC TTC GGT CGT ATT ATT TCG CGT TGC GTA C
RAR-b GGG ATT AGA ATT TTT TAT GCG AGT TGT TAC CCC GAC GAT ACC CAA AC TGT CGA GAA CGC GAG CGA TTC G
RASSF1A GCG TTG AAG TCG GGG TTC CCC GTA CTT CGC TAA CTT TAA ACG ACA AAC GCG AAC CGA ACG AAA CCA
Stratifin
14-3-3s
GAA GGT TAA GTT GGT AGA GTA GGT CGA AC AAC TAC TAA AAA CAA ATT TCG CTC TTC G CTC GCC CTT CTC CAC GAC GCC
THBS1 CGA CGC ACC AAC CTA CCG GTT TTG AGT TGG TTT TAC GTT CGT T ACG CCG CGC TCA CCT CCC T
Timp3 GCG TCG GAG GTT AAG GTT GTT CTC TCC AAA ATT ACC GTA CGC G AAC TCG CTC GCC CGC CGA A
TMS1 TTG GAG GGT AAC GGA TCG GGG C CCC GCT ACA ACC GCC GAC CAA A GAC TCC GAA ACG AAA CCT AAA CTC CCC
b-actin TGG TGA TGG AGG AGG TTT AGT AAG T AAC CAA TAA AAC CTA CTC CTC CCT TAA ACC ACC ACC CAA CAC ACA ATA ACA AAC ACA
doi:10.1371/journal.pone.0010828.t001
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salivary tissue. Ten genes (APC, GSTP, DCC, MLH1, b -Catenin,
MGMT, p16, RAR-b, RASSF1A and THBS1) displayed no
methylation in the 17 normal tissue samples, while 2 genes
(HIC1 and Stratifin) showed methylation in all 17 normal tissue
samples.
The most significantly methylated tumor type was SDC, with at
least 5 loci methylated in all of the 18 samples and a total of 15
(83.3%) samples methylated at 7 or more loci. The other two types of
malignant tumor tested, ACC and MEC, demonstrated less
methylation than SDC. For ACC, at least three loci were methylated
in 15 (88.2%) of the 17 samples but only 4 (23.5%) samples were
methylated at 7 or more loci. Because of the relatively small sample
size and high number of variables, we could not demonstrate
statistical significance in the tumor cohorts when taken individually.
Figure 1 depicts a graphic illustration of the methylation quotient
distribution plots by gene and tumor type.
Methylation Levels Across Tumor Type
When dividing the groups into normal, benign (PA), and
malignant (ACC, MEC, SDC), one would expect to see an
increasing incidence of methylation or MQ across these three
categories. The Cochran-Armitage test was used to test for
increasing methylation frequency (in a binary fashion), and 7 genes
met statistical significance (APC, GSTP1, Mint1, P16, PGP 9.5,
RAR-b, and Timp3). The Cuzick test accounted for the MQ level
as a continuous variable, and 8 genes met significance (APC, HIC1,
Mint1, PGP 9.5, RAR-b, and Timp3). P16 and RASSF1A are
interesting as they could be specific for tumors as all of the normal
samples showed no methylation. However, there was methylation
in benign and malignant SGTs, though they failed to meet
statistical significance on both of the statistical tests (p16 was
significant on the Cochran-Armitage test). Five genes showed
overlapping significance in both tests (APC, Mint1, PGP9.5, RAR-b,
and Timp3). Interestingly, FHIT showed a reverse correlation, with
higher levels and frequency of methylation seen in the normal
samples than the benign or malignant tumors. The summary data
is shown in Table 5. There were no apparent correlations between
any of these genes’ methylation status or level and clinical or
pathologic findings, including environmental factors such as age
and smoking, perhaps due to the sample size limitations.
Discussion
Promoter methylation has emerged as one of the key
mechanisms of TSG silencing in many cancers, and we sought
to further elucidate its role in SGTs. The aims of this study were to
identify and characterize the methylation status of a broad panel of
TSG promoters in several different SGTs. In order to accomplish
this, we used qMSP to evaluate a panel of 19 TSGs among true
SGT malignancies (ACC, MEC, SDC), one benign SGT type
(PA), as well as in normal salivary tissue.
Table 2. Clinical and pathologic characteristics of patient populations.
Category Subcategory Normal PA ACC MEC SDC
Patients, n 17 26 17 17 18
Age, yr, median (range) 58.7 (42–77) 48.5 (12–74) 58 (25–83) 43 (15–77) 61 (31–85)
Sex, n (%) Male 10 (58.8%) 9 (34.6%) 9 (53%) 6 (35.3%) 11 (61.1%)
Female 7 (41.2%) 17 (65.4%) 8 (47%) 11 (64.7%) 7 (38.9%)
Smoking Status Never 3 (17.6%) 13 (50%) 10 (58.8%) 11 (64.7%) 4 (44.4%)
Former 4 (23.6%) 8 (30.8%) 4 (23.5%) 2 (11.8%) 1 (5.6%)
Current 7 (41.2%) 5 (19.2%) 3 (17.6%) 2 (11.8%) 6 (33.3%)
Unknown 3 (17.6%) - - 2 (11.8%) 3 (16.7%)
Salivary Gland Involvement, n (%) Parotid 22 (84.6%) 5 (29.4%) 10 (58.8%) 16 (88.9%)
Submandibular 1 (3.8%) 2 (11.8%) 2 (11.8%) 1 (5.6%)
Minor 3 (11.5%) 10 (58.8%) 5 (29.4%) 1 (5.6%)
Stage, n(%) I n/a 2 (11.8%) 9 (53%) 0 (0%)
II n/a 4 (23.5%) 4 (23.5%) 2 (11.1%)
III n/a 1 (5.9%) 3 (17.6%) 0 (0%)
IV n/a 7 (41.2%) 0 (0%) 16 (88.9%)
Unknown n/a 3 (17.6%) 1 (5.9%) 0 (0%)
Local Recurrence, n (%) Yes 1 (3.8%) 2 (11.8%) 1 (5.9%) 8 (44.4%)
No 25 (96.2%) 15 (88.2%) 16 (94.1%) 10 (55.6%)
Metastasis, n (%) Yes 0 (0%) 10 (58.8%) 2 (11.8%) 8 (44.4%)
PA - Pleomorphic Adenoma, ACC - Adenoid Cystic Carcinoma, MEC - Mucoepidermoid Carcinoma, SDC - Salivary Ductal Carcinoma.
doi:10.1371/journal.pone.0010828.t002
Table 3. Average number of methylated genes per tumor
type.
Tissue Type Sample Size
Average # of Methylated
Genes
{ (Std Dev)
Normal 17 4.53 (2.0)
PA 26 5 (2.2)
ACC 17 5.41 (2.4)
MEC 17 4.47 (2.6)
SDC 18 9.61* (3.0)
{Calculated as any level of methylation detected within the 19 genes tested.
*significantly different than normal, p,0.0003.
doi:10.1371/journal.pone.0010828.t003
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hypermethylation. This is also the first study to include an extensive
panel of TSGs (19 in our study), whereas most of the previous studies
focused only on a single gene or a small panel of genes.
Previous studies did indicate a role for hypermethylation of
TSG promoters in SGT carcinogenesis. Williams et al. evaluated
102 tumor samples and 29 normal salivary glands using non-
quantitative MSP for four TSGs (DAPK, MGMT, RAR-b, and
RASSF1A). This study detected hypermethylation of RAR-b (29%)
and RASSF1A (48%) for SDC and hypermethylation of RASSF1A
(43%) for ACC [18]. In a study by Guo et al., hypermethylation
induced inactivation of the p16 gene was reported in 34.2% (13 of
38) of the MEC studied [19]. Uchida et al. demonstrated that
downregulation of 14-3-3 s via hypermethylation may be critical
in the development of ACC. A similar study by Li et al., showed
promoter methylation of p16 (47%), RASSF1A (41%) and DAPK
(21%) in a cohort of 60 patients with ACC and indicated that
RASSF1A may be linked to metastasis potential in ACC [7,8].
Our results showed considerable heterogeneity in frequency and
quantity of methylation at individual tumor suppressor genes in
different SGT types. Smoking and age were not found to globally
affect any methylation profiles in this cohort. We found SDC to be
the most methylated tumor type, which showed significantly
higher methylation frequency and level across our 19-gene panel.
Interestingly, when looking at the average levels across the 19
genes tested, the normal tissue values were comparable to ACC,
MEC, and PA. This finding highlights the importance of including
normal controls, particularly when there are likely tissue-specific
differences in methylation.
Five genes were found to have significantly increasing
methylation status (frequency and level) when comparing normal,
benign, and malignant salivary tissue: APC, Mint1, PGP 9.5, RAR-
Table 4. Frequency of positive cases [n (%)] and distribution of Methylation Quotient levels [Mean (range)] in normal parotid
tissue, PA, ACC, MEC, and SDC.
Gene Normal (n=17) ACC (n=17) MEC (n=17) PA (n=26) SDC (n=18)
n( % )
Mean
(range) n (%)
Mean
(range) n (%)
Mean
(range) n (%)
Mean
(range) n (%)
Mean
(range)
Aim1 2 (11.8) 101.5
(0–1570.9)
0 (0) 0 (0-0) 0 (0) 0 (0-0) 3 (11.5) 0.9 (0–14.7) 2 (11.1) 10.3
(0–177.7)
APC 0 (0) 0 (0-0) 6 (35.3) .6 (0–3.6) 2 (11.8) 0.4 (0–4.9) 9 (34.6) 39.2 (0–915.9) 15 (83.3) 1606.5
(0–9289.6)
b-catenin 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 0 (0-0) 4 (22.2) 135.9
(0–969.9)
DAP-K 7 (41.2) 4.8
(0–20.4)
6 (35.3) 3.2 (0–27.3) 4 (23.5) 1.8
(0–10.3)
3 (11.5) 0.5 (0–8.8) 12 (66.7) 148.1
(0–727.1)
DCC 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0)
FHIT 15 (88.2) 168.0
(0–309.9)
4 (23.5) 19.4
(0–103.3)
3 (17.6) 15.7
(0–116.7)
7 (26.9) 15.4 (0–86.7) 6 (33.3) 133.6
(0–1168.5)
GSTP1 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 8 (44.4) 110.9
(0–633.7)
HIC1 17 (100) 530.3
(182.3–1164.3)
16 (94.1) 461.6
(0–1150.7)
17 (100) 422.4
(72.8–1036.7)
26 (100) 907.8
(492.7–1843.0)
18 (100) 563.0
(162.0–1735.2)
MGMT 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 2 (11.1) 117.2
(0–1248.6)
Mint1 3 (17.6) 6.0
(0–37.5)
9 (52.9) 19.9
(0–111.9)
5 (29.4) 147.2
(0–2199.0)
10 (38.5) 6.4
(0–24.3)
11 (61.1) 2898.5
(0–44012.6)
MLH1 0 (0) 0 (0-0) 2 (11.8) 1.6 (0–20.8) 1 (5.9) 0.3 (0–4.9) 3 (11.5) 7.6
(0–128.1)
2 (11.1) 0.8 (0–8.9)
p16 0 (0) 0 (0-0) 0 (0) 0 (0-0) 2 (11.8) 28.3
(0–463.3)
1 (3.8) 19.8
(0–514.2)
6 (33.3) 633.1
(0–5761.5)
PGP 9.5 3 (17.6) 0.5 (0–4.1) 5 (29.4) 13.7
(0–156.8)
2 (11.8) 1.0 (0–13.2) 10 (38.5) 28.7
(0–274.0)
16 (88.9) 583.2
(0–2133.5)
RAR-b 0 (0) 0 (0-0) 3 (17.6) 8.0 (0–77.7) 4 (23.5) 342.0
(0–2934.0)
2 (7.7) 12.6
(0–313.2)
14 (77.8) 1587.2
(0–6284.7)
RASSF1A 0 (0) 0 (0-0) 6 (35.3) 87.6
(0–788.7)
1 (5.9) 31.8 (0–539.8) 14 (53.8) 103.6
(0–606.6)
12 (66.7) 969.7
(0–3952.4)
Stratifin
14-3-3s
17 (100) 1407.8
(674.4–2439.8)
17 (100) 930.8
(0–2622.9)
17 (100) 1248.7
(0–2478.7)
26 (100) 1732.3
(607.7–6199.2)
18 (100) 1262.9
(440.1–2235.9)
THBS1 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 0 (0) 0 (0-0) 2 (11.1) 139.7 (0–1365.2)
Timp3 6 (35.3) 6.4 (0–22.7) 10 (58.8) 14.7
(0–220.2)
12 (70.6) 10.3
(0–89.4)
7 (26.9) 1.7
(0–18.3)
12 (66.7) 220.0 (0–1274.0)
TMS1 7 (41.2) 25.2 (0–88.9) 9 (52.9) 15.0
(0–189.8)
7 (41.2) 3.1
(0–9.4)
9 (34.6) 1.6 (0–9.1) 13 (72.2) 153.9 (0–838.6)
*Note: Frequency of positive cases is expressed as number and (%). Distribution of MQ levels is the ratio of the methylation of the gene to b-actin 61,000.
doi:10.1371/journal.pone.0010828.t004
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to exhibit promoter methylation in SGTs [18]. Loss of expression
of APC, or adenomatous polyposis coli, via promoter hypermethy-
lation has been previously described in head and neck squamous
cell carcinoma, bladder cancer, prostate cancer, lung cancer, and
several other cancer types [31,32,33,34]. This TSG encodes a
large protein with multiple cellular functions including signal
transduction in the Wnt-signaling pathway. In one study, there
were sequence mutations of APC in 2/20 ACC cases, but promoter
methylation was not studied [35].
Mint1 is a protein trafficking molecule, and its methylation has
been implicated in many other tumor types [36,37,38,39]. The
mechanism of how it suppresses growth is not known. PGP9.5, also
known as UCHL1 or ubiquitin carboxyl-terminal hydrolase L1, is a
neuro-specific peptide that functions to remove ubiquitin from
ubiquinated proteins and prevents them from targeted degrada-
tion by proteosomes [40]. This gene has also been implicated in
the carcinogenesis of many tumor types, including head and neck
squamous cell carcinoma, as well as pancreatic, lung, colorectal,
and ovarian carcinomas [40,41,42,43]. Timp3, or tissue inhibitor
of metalloproteinases-3, has been found to inhibit angiogenesis
through a VEGF mediated pathway [44], and has been found to
be silenced through promoter hypermethylation in a variety of
tumor types [45,46,47,48]. To our knowledge, this is the first time
that these three genes (Mint1, PGP 9.5, and Timp3) have been
implicated in salivary gland tumorigenesis.
Figure 1. Methylation by tissue and tumor type. Overview of the log methylation quotients of normal (N), benign pleomorphic adenoma (PA),
and cancerous (CA) salivary gland tumors from the 19 tumor suppressor genes tested.
doi:10.1371/journal.pone.0010828.g001
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normal parotid tissue although they did not meet robust statistical
significance. They could be further tested in a larger cohort for
potential biomarker development for SGTs as none of the normal
tissue samples showed promoter methylation. These two gene
promoters may not have met statistical significance for differential
methylation due to the limited samples examined and the
relatively low frequency of methylation in these tissues. Previous
reports have shown RASSF1A to ne hypermethylated and
correlating with metastatic potential as well as tumor grade and
3-year survival [8,14,18].
While the significance of promoter methylation in cancer is a
relatively recent discovery, it already has a wide range of possible
clinical applications. It can serve as an excellent means of
molecular detection of cancer in serum, saliva, and urine samples
[49,50]. In prostate cancer, promoter hypermethylation is an
independent prognostic factor for relapse in cancer patients
following radical prostatectomy [51]. In some instances, hyper-
methylation of certain TSG promoters predicts the response of
tumors to therapy, as is the case with MGMT hypermethylation
and response of primary gliomas to 1,2-bis(2-chloroethyl)-1-
nitrosourea (BCNU) and temozolomide [52,53]. It is our hope
that similar findings in methylation of TSG promoters in primary
SGTs might convey comparable prognostic and therapeutic
implications.
In conclusion, our study is the first QMSP analysis of multiple
TSGs in salivary gland tumors. The relatively high frequency and
degree of methylation of some TSGs in normal salivary tissue
highlights the tissue specificity of these genes, as well as the need
for controlled experiments. Our results indicate that APC, Mint1,
PGP 9.5, RAR-b, and Timp3 are particularly important in SGTs,
and may contribute to salivary gland carcinogenesis. Further study
is needed to elucidate the mechanisms by which they contribute to
tumorigenesis. Larger sample cohorts are required to determine
their possible roles as markers of detection or prognosis.
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